Glycosylation has been identified as an early stage biomarker in AD [64], and is correlated with the severity of amyloid and tau pathology in both preclinical and clinical AD patients [65]; recent evidence implies that glycosylation of proteins and a number of other AD-related molecules is altered in AD, suggesting a potential implication of this process in disease pathology [66,67,68]. Here, MAPT is linked to Alzheimer disease.